Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Transformed ICPbio Creating Wealth

October 31 2006

Media statement


Transformed ICPbio Creating Wealth

Statement based on addresses delivered at today’s annual meeting of
ICP Biotechnology Limited in Auckland

ICPbio’s new plasma fractionation facility will have the capability to convert a tonne of animal plasma, purchased as raw material at $3000 a tonne, into range of high value protein products valued at more than $250,000 on the international market.

At today’s annual meeting of the biotechnology company held in Auckland, shareholders were told the new state-of-the-art fractionation plant was “on track” to commence operations in mid November.

When fully operational in early 2007, the plant, the largest of its type in the world, will operate on a 24/7 basis and be capable of processing more than 12 tonnes of animal plasma a week.

Chairman Roger Gower told the meeting that by the end of the current financial year the company will be “well into profit, and consolidating its position as a global biotechnology provider”.

“We are creating wealth now, not at some future, yet to be determined date.”

He said “outstanding progress” had been made in transforming ICPbio from being a successful but modest New Zealand biotechnology company into a global manufacturer of quality biological products.

“We have quietly gone about putting in place the building blocks that will achieve success and create wealth.

“We are now operating in a world market valued at US$2 billion, and marketing our products to more than 40 countries in North America and South America, Asia and Europe.”

Managing Director Dr Earl Stevens said that the company had already added an additional 26 serum and plasma protein based cell growth and cell culture products to its foundation product range of 20.

“Key drivers of future revenue will be two streams of activity, one based around sterile filtration and the other fractionation of plasma.

“Both activities produce high value proteins that are the building blocks for human and animal health products.

“These activities in turn will lead us down the path of new molecules, active pharmaceutical intermediates and antibodies with pharmaceutical applications.”

He said the recent $402,000 Foundation for Research, Science and Technology grant received by the company would go towards developing new plasma protein products to control bleeding, and be supplied to companies making products for the human health market.

Dr Stevens described ICPbio as being at the “boring” end of the biotechnology spectrum in that is supplied the day-to-day products used by those at the cutting edge, and those engaged in the manufacture of animal and human health products.

“It is the commercially safe and dependable end, and is revenue positive. We combine low risk with potentially high return.”

At the meeting, independent director Alistair Ward, was re-elected, and Brent King and Grant Baker, associated with publicly listed Viking Capital, ICPbio’s second largest shareholder, were elected to the board.

ENDS

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

BusinessDesk: Body massages and Uber are in, DVDs are out, says Stats NZ

Statistics New Zealand has rejigged the consumers price index basket in its latest three-year review, adding body massages, Airbnb and Uber and removing DVD and Blu-Ray players…More>>

ALSO:


StuffMe: Commerce Commission Welcomes Dismissal Of Merger Appeal

In a summary of their judgment released today, Justice Dobson and lay member Professor Martin Richardson dismissed the appellants’ process criticisms and found the Commission was entitled to place significant weight on the prospect of reduced quality of the products produced by the merged entity. More>>

ALSO:

Digital Futures: New Chief Technology Officer Role Created

Communications Minister Clare Curran has called for expressions of interest for the new role of Chief Technology Officer position to help drive a forward-looking digital agenda for New Zealand. More>>

Dry: Beef + Lamb Launches Drought Resources

The resources include a fact sheet outlining strategies to manage and mitigate the effects of drought, coping with stress on the farm and advice on feed requirements and animal welfare during the dry period. More>>

ALSO:

InternetNZ: Net Neutrality Failure In US "Will Hurt All Users"

InternetNZ Chief Executive Jordan Carter has condemned the decision by the United States communications regulator to undo 2015 open Internet rules, warning that all Internet users will end up worse off as a result. More>>

ALSO: